1. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Prediction of cancer incidence and mortality in Korea, 2014. Cancer Res Treat. 2014; 46:124–130. PMID:
24851103.
Article
2. Hedegaard J, Thorsen K, Lund MK, Hein AM, Hamilton-Dutoit SJ, Vang S, et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS One. 2014; 9:e98187. PMID:
24878701.
Article
3. Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P. Unlocking the archive: gene expression in paraffin-embedded tissue. J Pathol. 2001; 195:66–71. PMID:
11568892.
4. Nechifor-Boilă AC, Loghin A, Vacariu V, Halaţiu VB, Borda A. The storage period of the formalin-fixed paraffin-embedded tumor blocks does not influence the concentration and purity of the isolated DNA in a series of 83 renal and thyroid carcinomas. Rom J Morphol Embryol. 2015; 56(2 Suppl):759–763. PMID:
26429169.
5. Lee JE, Kim JH, Hong EJ, Yoo HS, Nam HY, Park O. National Biobank of Korea: quality control programs of collected-human biospecimens. Osong Public Health Res Perspect. 2012; 3:185–189. PMID:
24159512.
Article
6. Scolnick JA, Dimon M, Wang IC, Huelga SC, Amorese DA. An efficient method for identifying gene fusions by targeted RNA sequencing from fresh frozen and FFPE samples. PLoS One. 2015; 10:e0128916. PMID:
26132974.
Article
7. Ribeiro-Silva A, Zhang H, Jeffrey SS. RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies. BMC Mol Biol. 2007; 8:118. PMID:
18154675.
Article
8. Rupp GM, Locker J. Purification and analysis of RNA from paraffin-embedded tissues. Biotechniques. 1988; 6:56–60. PMID:
2483655.
9. Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist. 2010; 15:457–465. PMID:
20421264.
Article
10. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351:2817–2826. PMID:
15591335.
Article
11. Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genomics. 2015; 8:54. PMID:
26297356.
Article
12. Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res. 2014; 20:511–521. PMID:
24443618.
Article
13. Chung JY, Braunschweig T, Hewitt SM. Optimization of recovery of RNA from formalin-fixed, paraffin-embedded tissue. Diagn Mol Pathol. 2006; 15:229–236. PMID:
17122651.
Article
14. Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med. 2006; 27:126–139. PMID:
16469371.
Article
15. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006; 7:3. PMID:
16448564.
Article
16. Guo Y, Li CI, Ye F, Shyr Y. Evaluation of read count based RNAseq analysis methods. BMC Genomics. 2013; 14(Suppl 8):S2.
Article
17. Rosen PP, Menendez-Botet CJ, Nisselbaum JS, Urban JA, Miké V, Fracchia A, et al. Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res. 1975; 35(11 Pt 1):3187–3194. PMID:
171066.